Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CJC-1295 and Sermorelin — mechanism, dosing, side effects, legal status, and pricing.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates sustained growth hormone secretion. The no-DAC (Drug Affinity Complex) version provides pulsatile GH release that more closely mimics natural physiology.
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH. It was previously FDA-approved for diagnosing and treating pediatric GH deficiency and is now widely used in anti-aging medicine.
CJC-1295
Sermorelin
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Clinical trials have shown CJC-1295 increases GH and IGF-1 levels by 200–1000% without significantly altering other pituitary hormones. It is commonly studied in combination with GHRPs like ipamorelin for synergistic effects.
Previously FDA-approved (Geref) for pediatric GH deficiency before being discontinued for commercial reasons. Clinical data supports improved body composition, sleep quality, and skin elasticity in adults. It is one of the most well-characterized GH secretagogues.
CJC-1295 and Sermorelin are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs